Linking In Vitro Models of Endothelial Dysfunction with Cell Senescence
Francisco R. Jimenez Trinidad,
Marta Arrieta Ruiz,
Núria Solanes Batlló,
Àngela Vea Badenes,
Joaquim Bobi Gibert,
Antoni Valera Cañellas,
Mercè Roqué Moreno,
Xavier Freixa Rofastes,
Manel Sabaté Tenas,
Ana Paula Dantas,
Olga Tura-Ceide,
Montserrat Rigol Muxart
Affiliations
Francisco R. Jimenez Trinidad
Cardiology Department, Institute Clinic Cardiovascular (ICCV), Hospital Clinic, Institute d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain
Marta Arrieta Ruiz
Cardiology Department, Institute Clinic Cardiovascular (ICCV), Hospital Clinic, Institute d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain
Núria Solanes Batlló
Cardiology Department, Institute Clinic Cardiovascular (ICCV), Hospital Clinic, Institute d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain
Àngela Vea Badenes
Department of Pulmonary Medicine, Servei de Pneumologia, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain
Joaquim Bobi Gibert
Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, 3015 Rotterdam, The Netherlands
Antoni Valera Cañellas
Cardiology Department, Institute Clinic Cardiovascular (ICCV), Hospital Clinic, Institute d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain
Mercè Roqué Moreno
Cardiology Department, Institute Clinic Cardiovascular (ICCV), Hospital Clinic, Institute d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain
Xavier Freixa Rofastes
Cardiology Department, Institute Clinic Cardiovascular (ICCV), Hospital Clinic, Institute d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain
Manel Sabaté Tenas
Cardiology Department, Institute Clinic Cardiovascular (ICCV), Hospital Clinic, Institute d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain
Ana Paula Dantas
Cardiology Department, Institute Clinic Cardiovascular (ICCV), Hospital Clinic, Institute d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain
Olga Tura-Ceide
Department of Pulmonary Medicine, Servei de Pneumologia, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain
Montserrat Rigol Muxart
Cardiology Department, Institute Clinic Cardiovascular (ICCV), Hospital Clinic, Institute d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain
Endothelial cell dysfunction is the principal cause of several cardiovascular diseases that are increasing in prevalence, healthcare costs, and mortality. Developing a standardized, representative in vitro model of endothelial cell dysfunction is fundamental to a greater understanding of the pathophysiology, and to aiding the development of novel pharmacological therapies. We subjected human umbilical vein endothelial cells (HUVECs) to different periods of nutrient deprivation or increasing doses of H2O2 to represent starvation or elevated oxidative stress, respectively, to investigate changes in cellular function. Both in vitro cellular models of endothelial cell dysfunction-associated senescence developed in this study, starvation and oxidative stress, were validated by markers of cellular senescence (increase in β-galactosidase activity, and changes in senescence gene markers SIRT1 and P21) and endothelial dysfunction as denoted by reductions in angiogenic and migratory capabilities. HUVECs showed a significant H2O2 concentration-dependent reduction in cell viability (p p 2O2 of 400 to 1000 μM resulted in impaired angiogenic and migratory potentials. These models will enable improved physiological studies of endothelial cell dysfunction, and the rapid testing of cellular efficacy and toxicity of future novel therapeutic compounds.